Nanobodies in cancer

For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and...

Full description

Saved in:
Bibliographic Details
Published inSeminars in immunology Vol. 52; p. 101425
Main Authors Verhaar, Elisha R., Woodham, Andrew W., Ploegh, Hidde L.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. The small size of nanobodies (∼15 kDa), their stability, ease of manufacture and modification for diverse formats, short circulatory half-life, and high tissue penetration, coupled with excellent specificity and affinity, account for their attractiveness. Here we review applications of nanobodies in the sphere of tumor biology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:1044-5323
1096-3618
DOI:10.1016/j.smim.2020.101425